SerpinB1 is critical for neutrophil survival through cell-autonomous inhibition of cathepsin G by Baumann, Mathias et al.
  1 
Title: SerpinB1 is critical for neutrophil survival through cell autonomous inhibition of 
cathepsin G 
 
Running title: serpinB1 shields PMNs against CG-mediated death 
 
Authors: Mathias Baumann1,2, Christine T.N. Pham3 and Charaf Benarafa1 
 
Affiliations: 1 Theodor Kocher Institute, University of Bern, 3012 Bern, Switzerland 
 2 Graduate School for Cellular and Biomedical Sciences, University of 
Bern, Switzerland 
3 Division of Rheumatology, Department of Internal Medicine, 
Washington University School of Medicine, Saint Louis, Missouri 
63110, USA. 
 
 
Please send correspondence and reprints to 
Charaf Benarafa, DVM PhD 
Theodor Kocher Institute 
Freiestrasse 1 
3006 Bern, Switzerland 
charaf.benarafa@tki.unibe.ch 
Tel: +41 31 631 4148 
Fax: +41 31 631 3799 
 
 
Keywords.  Neutropenia, serpin, apoptosis, granulopoiesis, bone marrow 
 
Text word count:  3884 
Abstract word count:  200 
Number of figures:  6 
Number of tables:  0 
Number of references: 50 
 
Number of suppl. figures: 6 
s
o
u
r
c
e
:
 
ht
tp
s:
//
do
i.
or
g/
10
.7
89
2/
bo
ri
s.
46
47
4 
| 
do
wn
lo
ad
ed
: 
13
.3
.2
01
7
  2 
Abstract 
The bone marrow (BM) holds a large reserve of polymorphonuclear neutrophils 
(PMNs) that are rapidly mobilized to the circulation and tissues in response to danger 
signals. SerpinB1 is a potent inhibitor of neutrophil serine proteases (NSPs) 
neutrophil elastase (NE) and cathepsin G (CG). SerpinB1-deficiency (sB1-/-) results 
in a severe reduction of the BM PMN reserve and failure to clear bacterial infection. 
Using BM chimera, we found that serpinB1 deficiency in BM cells was necessary and 
sufficient to reproduce the BM neutropenia of sB1-/- mice. Moreover, we showed that 
genetic deletion of CG, but not NE, fully rescued the BM neutropenia in sB1-/- mice. 
In mixed BM chimera and in vitro survival studies, we showed that CG modulates 
sB1-/- PMN survival through a cell-intrinsic pathway. In addition, membrane 
permeabilization by lysosomotropic agent LLME that allows cytosolic release of 
granule contents was sufficient to induce rapid PMN death through a CG-dependent 
pathway. CG-mediated PMN cytotoxicity was only partly blocked by caspase 
inhibition suggesting that CG cleaves a distinct set of targets during apoptosis. In 
conclusion, we have unveiled a new cytotoxic function for the serine protease CG 
and showed that serpinB1 is critical for maintaining PMN survival by antagonizing 
intracellular CG activity.  
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Introduction 
Polymorphonuclear neutrophil granulocytes (PMNs) are essential components of the 
innate immune response to infection. PMNs are relatively short-lived leukocytes that 
originate from hematopoietic stem cells in the bone marrow (BM) in a process called 
granulopoiesis. Granulopoiesis proceeds through a proliferative phase followed by a 
maturation phase. After maturation, the BM retains a large reserve of mature PMNs, 
which includes over 90% of the mature PMNs in the body while only a small 
proportion (1-5%) is in the blood1,2. Even in non-inflammatory conditions, 
granulopoiesis is remarkable as more than 1011 PMNs are produced daily in an adult 
human only to be disposed of, largely unused, a few hours later3. There is evidence 
that the majority of PMNs produced never reaches the circulation and die within the 
BM4. Congenital or acquired forms of neutropenia are associated with the highest 
risks of bacterial and fungal infection5, indicating a strong evolutionary pressure to 
maintain granulopoiesis at high levels and sustain a large mobilizable pool of PMNs 
in the BM.  
In steady state, PMNs die by apoptosis, a form of programmed cell death that allows 
for the safe disposal of aging PMNs and their potentially toxic cargo. Like in other 
cells, caspases participate in the initiation, amplification and execution steps of 
apoptosis in PMNs6,7. Interestingly, non-caspase cysteine proteases calpain and 
cathepsin D were reported to induce PMN apoptosis through activation of caspases8-
11. In addition, PMNs carry a unique set of serine proteases (NSPs) including 
elastase (NE), cathepsin G (CG) and proteinase-3 (PR3) stored active in primary 
granules. There is strong evidence for a role of NSPs in killing pathogens and 
inducing tissue injury when released extracellularly12-14. In contrast, the function of 
NSPs in PMN homeostasis and cell death remains elusive. In particular, no defects 
in granulopoiesis or PMN homeostasis have been reported in mice deficient in 
cathepsin G (CG-/-)15, neutrophil elastase (NE-/-)16,17 or dipeptidylpeptidase I (DPPI-/-), 
which lack active NSPs18. We have recently shown that mice lacking the serine 
protease inhibitor serpinB1 (sB1-/-) have reduced PMN survival in the lungs following 
Pseudomonas infection and that these mice have a profound reduction in mature 
PMN numbers in the BM19,20. SerpinB1, also known as MNEI (monocyte neutrophil 
elastase inhibitor), is expressed at high levels in the cytoplasm of PMNs and is one 
of the most potent inhibitors of NE, CG and PR-321,22. In this study, we tested the 
hypothesis that serpinB1 promotes PMN survival by inhibiting one or several NSPs 
and we discovered a novel regulatory pathway in PMN homeostasis in vivo.  
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Methods 
Mice. Generation of serpinB1-/- (serpinb1atm1.1Cben) mice in 129S6/SvEvTac (129S6) 
and backcrossing in C57BL/6J background were described previously19,20. Mice 
deficient in cathepsin G (CG-/-) (Ctsgtm1Ley)15 and dipeptidylpeptidase I (DPPI-/-) 
(Ctsctm1Ley)23 were provided by Christine Pham (Washington University, St Louis, 
MO). Neutrophil elastase deficient mice (NE-/-)(B6J-Elanetm1Sds)24, green fluorescent 
protein (GFP+) transgenic mice (B6-Tg(CAG-EGFP)1Osb) and CD45.1 (B6.SJL-Ptprca 
Pepcb/BoyJ) were obtained from the Jackson Laboratories. All animal studies were 
approved by the Cantonal Veterinary Office of Bern and conducted in accordance 
with the Swiss federal legislation on animal welfare. 
Flow cytometry and cell sorting. Leukocyte counts and hematopoietic lineage 
differential analysis of blood and bone marrow was performed in 8-week old mice. 
Equal numbers of males and females were included for each line. Blood (70µl) was 
collected from the retroorbital sinus of sedated mice using heparinized 
microhematocrit tubes. Total blood leukocyte, erythrocyte and platelet counts were 
performed at the central clinical laboratories of the veterinary faculty of the University 
of Bern. BM cells were harvested from femurs by flushing with cation-free HBSS 
supplemented with 1% FCS and counted in a Neubauer chamber. Isolated BM cells 
and whole blood were stained with fluorescently labeled antibodies (Biolegend and 
BD Biosciences) and analyzed on a FACScalibur flow cytometer (BD Biosciences) as 
described previously25. Briefly, leukocyte subsets percentages were determined 
within CD45+ cells as PMNs (CD11b+Ly-6Ghi), myelocytes (CD11b+Ly-
6GnegSSChiCD115neg), monocytes (CD115+) and B cells (CD19+ or CD45RB220+). 
Data was analyzed and presented using FlowJo (TreeStar). Flow sorting of PMNs, B 
cells and myelocytes was performed on single cell suspensions of BM leukocytes 
using a FACS Aria II sorter (BD Biosciences) at the flow cytometry core facility of the 
Department of Clinical Research of the University of Bern. 
Bone marrow chimera. For the generation of chimeric mice, recipient mice were 
lethally irradiated from a cesium source with 10 Gray using a Gammacell 40 Exactor 
(Theratronics). BM cells (10-20x106) from 8-13 week-old donor mice were injected 
into the retroorbital sinus of recipient mice 18 hr after irradiation. Antibiotics (1% 
Cotrim, Spirig Pharma AG) were added to the drinking water for 4 weeks and BM 
and blood populations were analyzed at least 8 weeks after BM transfer. 
Reconstitution efficiency was always greater than 95% based on flow cytometry 
analysis of recipient cells (CD45.1, CD45.2 or GFP). In mixed BM chimera, the 
relative percentage of WT (CD45.1) and sB1-/- (CD45.2) cell subsets were 
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determined as described in Suppl. Fig.S3. Since B cell numbers were not different in 
WT and sB1-/- mice and engrafted with a similar efficiency, B cells provided an 
internal control population to estimate the actual percentage of hematopoietic stem 
cell input of each genotype (% input) transplanted in each GFP mouse. 
Western blot. Sorted cells were washed and lysed (107/ml) in RIPA buffer with 
protease inhibitor cocktail (Roche). Lysates were resolved by SDS-PAGE under 
reducing conditions and immunoblotted using rabbit antiserum to serpinB120. Blots 
were stripped and restained with anti-β-actin antibody (Cell Signaling Technology). 
In vitro survival assays. BM cells were isolated by flushing femurs and tibias of 8-22 
week-old mice with HBSS. PMNs were enriched using a magnetic negative selection 
kit (EasySep, StemCell Technologies). Purity and viability of the purified neutrophils 
were assessed by flow cytometry and were typically 70-95% and >90%, respectively. 
Purified neutrophils were cultured in DMEM (4mM L-Glut, 25mM D-Glucose, 1mM 
Sodium Pyruvate)(GIBCO) containing 1% FCS at 0.5-1x106cells/ml in the presence 
or absence of the pan-caspase inhibitor Q-VD-OPh (SM Biochemicals LLC), CG 
inhibitor I (JNJ-10311795; RWJ-355871)(Merck Chemicals) or L-leucyl-L-leucine 
methyl ester (LLME)(G-2550; Bachem). Cytotoxic effects of human CG (Athens 
Research & Technology) were evaluated in serum-free medium. Effects of LLME 
were investigated using whole BM after erythrocyte lysis by NH4Cl. At the indicated 
time-points, cells were harvested and viability was assessed using AnnexinV-FITC 
and 7AAD. After gating on Ly-6G+ events, viable cells were identified as 
FSChi7AADnegAnnexinVneg, early apoptotic as FSChi7AADnegAnnexinV+ and late 
apoptotic/necrotic as 7AAD+, respectively (Suppl. Fig.S1). 
In vivo administration of G-CSF. Mice received daily intraperitoneal injections of 
recombinant murine G-CSF (500ng/mouse)(Invitrogen) or control saline for 5 days. 
Blood and BM were harvested 24hr after the last injection and analyzed as described 
above. 
Statistical analysis. All analyses were performed using GraphPad Prism Mac 4.0c 
(GraphPad, San Diego, CA). P<0.05 was considered statistically significant. 
Results 
SerpinB1 neutropenia is rescued by BM transfer 
We have previously shown that serpinB1 is expressed at highest levels in the 
granulocyte lineage and that sB1-/- mice have a profound reduction in BM mature 
PMN numbers despite normal granulopoiesis19. Because serpinB1 is also expressed 
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in many tissues and cell types21,26, we generated BM chimera to investigate the 
contribution of non-hematopoietic cells in sustaining PMN survival. WT mice were 
lethally irradiated and were transferred with WT or sB1-/- BM cells. Eight to ten weeks 
after BM transfer, mice reconstituted with sB1-/- cells recapitulated the defective PMN 
reserve of sB1-/- mice, whereas the mice reconstituted with WT cells had normal 
numbers of BM PMNs, indicating that serpinB1-deficiency in BM cells is sufficient to 
induce BM neutropenia in vivo (Fig.1A). In the reverse experiment, transfer of WT 
BM cells in irradiated sB1-/- mice restored a normal PMN reserve in the BM (Fig.1B). 
Overall, these results demonstrate that serpinB1-deficiency in the BM compartment 
is necessary and sufficient to reproduce the neutropenic defect of sB1-/- mice. 
Cathepsin G regulates neutrophil numbers in the bone marrow 
Since serpinB1 is an efficient inhibitor of NE, CG and PR3, we then examined PMN 
numbers in mice deficient in one or several NSPs in combination with serpinB1 
deletion. As expected, sB1-/- mice had significantly reduced numbers and percentage 
of mature PMNs in the BM compared to WT and heterozygous sB1+/- mice. In 
addition, PMN numbers were normal in mice deficient in either DPPI, NE or CG 
(Fig.2A,B). Dipeptidyl peptidase I (DPPI) is not inhibited by serpinB1 but is required 
for the activation of all NSPs and no NSP activity is detectable in DPPI-/- mice18,23. 
PMN counts in DPPI-/-.sB1-/- BM were significantly higher than in sB1-/- BM, 
suggesting that one or several NSPs contribute to the PMN survival defect. To 
examine the role of NSPs in this process, we crossed several NSP-deficient strains 
with sB1-/- mice. We found that NE.CG.sB1-/- mice had normal PMN numbers 
indicating that these NSPs play a key role in the defective phenotype of sB1-/- PMNs 
(Fig. 2A,B). Furthermore CG.sB1-/- mice showed normal PMN numbers whereas 
NE.sB1-/- mice retained the BM neutropenia phenotype indicating that CG, but not 
NE, plays a significant role in the death of sB1-/- PMNs (Fig. 2A,B).  In addition, the 
double-deficient NE.sB1-/- mice had significantly lower BM myelocyte numbers than 
sB1-/- mice while the myelocyte numbers in singly-deficient NE-/- and sB1-/- BM were 
normal (Fig.2C,D). These results suggest that NE may promote myeloid cell 
proliferation, an activity that is revealed only when serpinB1 is absent.  This complex 
interaction between sB1 and NE requires further investigation. On the other hand, B 
cell and monocyte numbers and relative percentage in the BM were largely similar in 
all genotypes (Suppl. Fig.S2). Total numbers of blood leukocytes, erythrocytes and 
platelets were normal in mice deficient in NSPs and/or serpinB1 (Suppl. Fig.S3). 
PMN numbers in blood were normal in sB1-/- mice in steady state and combined 
deficiency of NSPs did not significantly alter these numbers (Fig.2E,F). Taken 
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together, our results indicate that serpinB1 likely sustains the survival of post-mitotic 
PMNs through its interaction with CG. 
CG-mediated PMN death is cell-intrinsic 
We next generated mixed BM chimeras to measure PMN competitive survival as well 
as evaluating the potential by-stander effects of CG or serpinB1 released in the BM 
environment on the overall PMN survival in vivo. First, lethally irradiated GFP+ mice 
were reconstituted with a 1:1 mixture of WT (CD45.1) and sB1-/- (CD45.2) BM cells 
and analyzed 8-10 weeks after reconstitution. Recipient GFP+ cells were always <3% 
and excluded from the analysis (Suppl. Fig.S4). B cells of WT and sB1-/- origin were 
found in similar proportions in the BM, reflecting similar input of hematopoietic stem 
cells from the two donor genotypes. In contrast, the proportion of WT PMNs was 
significantly greater than the proportion of sB1-/- PMNs, indicating a robust survival 
advantage of the WT PMNs and negligible by-stander effect of WT cells on sB1-/- 
PMN survival (Fig.3A). Second, we transferred irradiated GFP+ mice with skewed 
ratios of WT and sB1-/- BM. We found that total PMN numbers in the BM negatively 
correlated with the percentage of sB1-/- input (reflected by the percentage of B cells 
of sB1-/- origin): when sB1-/- input was low, total PMN counts were similar to those of 
WT mice; conversely, when sB1-/- input was high, PMN numbers corresponded to 
those of sB1-/- mice (Fig.3B). Third, we found no survival defect of CG.sB1-/- PMNs 
compared to WT PMNs in vivo when reconstituted at equal ratios into GFP+ mice 
(Fig.3C). Finally, isolated BM PMNs were incubated in vitro with various 
concentrations of human CG. Extracellular CG failed to induce a significant increase 
in sB1-/- PMN death in vitro compared to WT PMNs (Fig.3D). Taken together, these 
results suggest that CG-mediated death in sB1-/- PMNs is cell intrinsic. 
CG-mediated PMN death proceeds independently of caspase activity 
Neutrophil apoptosis whether triggered by intrinsic or extrinsic pathways culminates 
in the activation of effector caspases6,7. We previously reported that sB1-/- PMNs 
isolated from the BM show increased spontaneous apoptosis and necrosis compared 
to WT PMNs after 16hr ex vivo19,20. To investigate whether increased sB1-/- PMN 
death was dependent on caspase activity, purified BM neutrophils were cultured in 
the presence of the pan-caspase inhibitor Q-VD-OPh27. In the absence of Q-VD-
OPh, we found no significant difference in the survival of WT and sB1-/- PMNs 
(survival of 31% at 24hr; 5% at 48hr; <1% at 72hr in both genotypes). Caspase 
inhibition significantly extended the survival of both WT and sB1-/- PMNs compared to 
untreated PMNs. However, caspase inhibition was significantly less effective in 
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increasing sB1-/- PMN survival compared to WT PMNs, with 32% vs 81% survival at 
72hr, respectively (Fig.4A). We then attempted to block CG activity using the cell 
permeable CG inhibitor I 28. Although CG inhibitor I at 10 and 30µM led to a small but 
significant increase in survival of sB1-/- PMNs, we observed simultaneous toxicity on 
WT PMN survival (Suppl Fig.S5) thus precluding further increase in inhibitor 
concentration. Since granule levels of CG are high in PMNs, sufficient concentrations 
of CG inhibitor may not have been reached to fully block CG activity. Therefore, we 
investigated whether genetic deletion of CG would affect sB1-/- PMN survival. We 
found that in the doubly-deficient CG.sB1-/- mice the absence of CG completely 
rescued the sB1-/- PMN survival defect, even in the presence of Q-VD-OPh (Fig.4B). 
Taken together, our results unveil a CG-dependent but caspase-independent death 
pathway in PMNs that is controlled by serpinB1. 
Granule membrane permeabilization induces CG-mediated death in PMNs 
To test whether granule disruption contributes to the serpinB1-regulated CG-
dependent cell death, BM cells were treated with the lysosomotropic agent Leu-Leu-
OMe (LLME). LLME accumulates in lysosomes where the acyl transferase activity of 
DPPI generates hydrophobic (Leu-Leu)n-OMe polymers that induce lysosomal 
membrane permeabilization (LMP) and cytotoxicity in granule bearing cells such as 
cytotoxic T-lymphocytes, NK cells and myeloid cells29,30. While the cytotoxic effect of 
LLME and other methyl ester derivatives on PMNs has long been described, the 
contribution of PMN granule serine proteases to this process following LMP is 
unknown. First, we confirmed that DPPI-deficiency was completely protective against 
LLME-induced cell death in PMNs (data not shown). Then, we found that LLME 
significantly decreased the survival of WT PMNs; however, this effect was even more 
pronounced in sB1-/- PMNs compared to WT PMNs (Fig.5A, left panel). In contrast, 
survival of CG-/- and CG.sB1-/- PMNs was identical to each other but significantly 
greater than that of WT PMNs (P<0.001 after 2 and 4 hr) (Fig.5A, middle panel). 
Finally NE.sB1-/- PMNs were more sensitive to LLME compared to NE-/- PMNs but 
deficiency in NE alone had no further effect on PMN survival in the presence of 
LLME when compared with WT PMN survival (Fig.5A, right panel) and the reduced 
survival of NE.sB1-/- PMNs is similar to that of sB1-/- PMNs, reflecting mainly the 
absence of serpinB1 (Fig.5A, right panel). In the presence of caspase inhibitor Q-VD-
OPh, a similar pattern was observed between the genotypes (Fig.5B). Furthermore, 
Q-VD-OPh failed to improve the survival of sB1-/- and NE.sB1-/- PMNs, whereas the 
survival of WT and NE-/- PMNs was significantly increased. In mice lacking CG, 
caspase inhibition had a modest effect on PMN survival (Fig. 5B). These results 
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suggest that the cytoplasmic release of CG upon LMP likely initiates cell death 
upstream and independent of caspases and this effect is especially evident when CG 
activity is unopposed in the absence of serpinB1. 
G-CSF therapy increases sB1-/- PMN numbers via enhanced granulopoiesis 
G-CSF therapy is an effective long-term treatment in many cases of severe 
congenital neutropenia (SCN) and it is also used to prevent chemotherapy-induced 
febrile neutropenia by enhancing PMN production. In addition, G-CSF delays 
neutrophil apoptosis by differentially regulating pro- and anti-apoptotic factors10. To 
test whether G-CSF could rescue sB1-/- PMN survival defect, WT and sB1-/- mice 
were treated with therapeutic doses of G-CSF or saline for five days and BM and 
blood PMNs were analyzed 24hr after the last injection. Total counts of myelocytes 
and PMNs were significantly increased in the BM of treated mice compared to their 
respective untreated genotype controls (Fig.6A,B). The increase in myelocyte 
numbers was identical in G-CSF treated WT and sB1-/- mice, indicating that G-CSF-
induced granulopoiesis proceeds normally in sB1-/- myeloid progenitors (Fig.6B). 
However, PMN counts of treated sB1-/- mice remained significantly lower than that of 
WT mice (Fig.6A). More strikingly, blood PMN numbers were increased only in G-
CSF treated WT  but not sB1-/- treated mice. In G-CSF-treated sB1-/- mice, blood 
PMN numbers were identical to the baseline numbers for sB1-/- mice (Fig.6C; Suppl 
Fig.S6). These results indicate that sB1-/- PMN precursor proliferation is normal in 
response to G-CSF therapy leading to expansion of the BM reserve to some extent. 
However, the lower number of PMNs in the BM and, particularly, the lack of a 
sustained blood neutrophilia suggest that G-CSF does not fully rescue the survival 
defect of mature sB1-/- PMNs. 
Discussion 
SerpinB1 is a member of the clade B serpins, a subfamily composed of leaderless 
proteins with nucleocytoplasmic localization. Clade B serpins are often expressed in 
cells that also carry target proteases, which led to the hypothesis that intracellular 
serpins protect against misdirected granule proteases and/or protect bystander cells 
from released proteases31. We previously reported that deficiency in serpinB1 is 
associated with reduced PMN survival in the BM and at inflammatory sites19,20. The 
evidence presented here demonstrates that the cytoprotective function of serpinB1 in 
PMNs is based on the inhibition of granule protease cathepsin G (CG). Deficiency in 
CG was sufficient to rescue the defect of sB1-/- mice as illustrated by normal PMN 
counts in the BM of double knockout CG.sB1-/- mice. We also showed that the 
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protease-serpin interaction occurred within PMNs. Indeed, WT PMNs had a greater 
survival over sB1-/- PMNs in mixed BM chimera, whereas the survival of CG.sB1-/- 
PMNs was similar to WT PMNs after BM transfer. SerpinB1 is an ancestral clade B 
serpin with a conserved specificity determining reactive center loop in all 
vertebrates32. Furthermore, human and mouse serpinB1 have the same specificity 
for chymotrypsin-like and elastase-like serine proteases21,22. Likewise, human and 
mouse CG have identical substrate specificities and the phenotype of CG-/- murine 
PMN can be rescued by human CG33. Therefore, it is highly likely that the 
antagonistic functions of CG and serpinB1 in cellular homeostasis observed in mice 
can be extended to other species. 
Extracellular CG was previously reported to promote detachment-induced apoptosis 
(anoikis) in human and mouse cardiomyocytes34. This activity is mediated through 
the shedding and transactivation of epidermal growth factor receptor (EGFR) and 
downregulation of focal adhesion signaling 35,36. In our study, exogenous human CG 
also induced PMN death in vitro but these effects were not enhanced in sB1-/- PMNs 
and the neutropenia associated with serpinB1 deficiency was principally cell-intrinsic. 
How intracellular CG induces PMN death remains to be fully investigated. However, 
our studies provide some indications on the potential pathways. Like other NSPs, the 
expression of CG is transcriptionally restricted to the promyelocyte stage during PMN 
development and NSPs are then stored in active form in primary azurophil 
granules37. Since serpinB1 is equally efficient at inhibiting NE, CG and PR3, it was 
surprising that deletion of CG alone was sufficient to achieve a complete reversal of 
the PMN survival defect in CG.sB1-/- mice. A possible explanation would be that CG 
gains access to targets more readily than other granule proteases. There is evidence 
that binding to serglycin proteoglycans differs between NE and CG resulting in 
altered sorting of NE but not CG into granules of serglycin-deficient PMNs38. Different 
interactions with granule matrix may thus contribute to differential release of CG from 
the granules compared to other NSPs. However, because sB1-/- PMNs have similar 
levels of CG and NE as WT PMNs20 and because LLME-induced granule 
permeabilization likely releases all granule contents equally, we favor an alternative 
interpretation where CG specifically targets essential cellular components that are 
not cleaved by the other serpinB1-inhibitable granule proteases. Upon granule 
permeabilization, we found that CG can induce cell death upstream of caspases as 
well as independent of caspases. CG was previously shown to activate caspase-7 in 
vitro and it functions at neutral pH, which is consistent with a physiological role in the 
nucleocytoplasmic environment39. Cell death induced by lysosomal/granule 
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membrane permeabilization has previously been linked to cysteine cathepsins in 
other cell types. However, these proteases appear to depend on caspase activation 
to trigger apoptosis and they function poorly at neutral pH, questioning their potential 
role as regulators cell death40. In contrast, CG-mediated cell death is not completely 
blocked by caspase inhibition, which is a property reminiscent of granzymes in 
cytotoxic T cells41. In fact, CG is phylogenetically most closely related to serine 
proteases granzyme B and H42. Granzymes have numerous nuclear, mitochondrial 
and cytoplasmic target proteins leading to cell death41 and we anticipate that this 
may also be the case for CG.  
Whether intracellular release of CG induces death in other cell types remains to be 
investigated. CG and CG-inhibitory serpins, such as serpinB1 and serpinB6, are also 
expressed in monocytes, dendritic cells and mast cells and the protease-serpin 
balance in these cells may be altered in specific stress conditions leading to cell 
death. Interestingly, human gzmH has a chymotrypsin-like activity similar to CG and 
was recently shown to be inhibited by serpinB1 in NK cells43. However, mice have 
many homologs of gzmB and gzmH that have diverged from their human 
counterparts44. Therefore it is yet unclear whether mouse serpinB1 would also inhibit 
one or several of mouse granzymes. In cancer cells, TNF-α mediated apoptosis has 
been associated with induction of CG expression and apoptosis was partly prevented 
by transfection with human squamous cell carcinoma antigen 2 (SCCA2)(serpinB4), 
a serum marker for advanced squamous cell carcinoma tumors. SCCA2 inhibits CG, 
although with lower second order rate constants than serpinB1 or serpinB622,45. 
These findings, while only associative, are reminiscent of the upregulation of 
serpinB9 in tumor cells as a protective strategy against CTL death mediated by 
gzmB and perforin46-48. Whether serpins’ inhibiton of CG activity in tumors contributes 
to anti-apoptotic resistance of cancer cells should be interesting to investigate.  
G-CSF therapy is successfully used to treat most congenital and acquired 
neutropenia through increased granulopoiesis, mobilization from the BM and 
increased survival of PMNs. Prosurvival effects of G-CSF includes the upregulation 
of anti-apoptotic Bcl-2 family members, which act upstream of the mitochondria and 
the activation of effector caspases. In sB1-/- mice, G-CSF levels in serum are 4-fold 
higher than in WT mice in steady state and this is accompanied by an upregulation of 
the anti-apoptotic Bcl-2 family member Mcl-1 in sB1-/- PMNs19. Here, G-CSF therapy 
significantly increased granulopoiesis in both WT and sB1-/- mice. However, the PMN 
numbers in treated sB1-/- BM and blood were significantly lower than those of treated 
WT mice, indicating only a partial rescue of the survival defect. This is consistent with 
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our findings that CG-mediated death can proceed independently of caspases and 
can thus bypass anti-apoptotic effects mediated by G-CSF.  
CG has largely been studied in association with antimicrobial and inflammatory 
functions due to its presence in PMNs12-14,49. In this context, we have previously 
shown that serpinB1 contributes to prevent increased mortality and morbidity 
associated with production of inflammatory cytokines upon infection with 
Pseudomonas aeruginosa and influenza A virus20,50. In this study, we demonstrate 
that serpinB1 inhibition of the primary granule protease CG in PMNs is essential for 
PMN survival and this ultimately regulates PMN numbers in vivo. Our findings also 
extend the roles of CG from antimicrobial and immunoregulatory functions to a novel 
role in inducing cell death.  
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Figures and figure legends 
 
 
 
Figure 1. Defective PMN reserve in BM chimera depends on serpinB1-
deficiency in the hematopoietic compartment. Flow cytometry analysis of major 
BM leukocyte subsets of lethally irradiated mice was performed 8-10 weeks after BM 
transfer. (A) Irradiated WT (CD45.1) mice were transferred with WT (filled circles) or 
sB1-/- (open circles) BM cells. (B) Irradiated WT (filled circles) and sB1-/- (open 
circles) mice both CD45.2 were transferred with WT (CD45.1) BM cells. Each circle 
represents leukocyte number for one mouse  and horizontal line indicates the 
median. Median subsets numbers were compared by Mann-Whitney test (* P< 0.05; 
*** P<0.001). 
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Figure 2. PMN and myelocyte numbers in BM and blood of mice deficient in 
NSPs and serpinB1. Cell counts and percentages were determined by flow 
cytometry analysis for BM PMNs (A,B), myelocytes (C,D) and blood PMNs (E,F) in 8 
week old mice. Each circle represents the value for one mouse, horizontal bars 
indicate median value for each genotype (BM: N=19-25; blood: N=18-35). The dotted 
line across the graph shows the median for WT mice. For each subset, median 
values of double and triple knockout mice lacking sB1 and one or several NSPs 
(open circles) were analyzed by one-way ANOVA followed by Dunnett’s comparison 
relative to reference column for sB1-/- mice († P<0.05; †† P<0.01). 
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Figure 3. CG-mediated sB1-/- PMN death is cell intrinsic. (A) The relative 
percentage of cells from each donor is shown for PMNs and B cells from irradiated 
GFP+ mice 8-10 weeks after transfer of 1:1 mixture of WT (CD45.1) and sB1-/- 
(CD45.2) BM. Data points are indicated for each mouse and means were compared 
by paired Student’s t-test (*** P<0.001). (B) Total PMN numbers in BM of irradiated 
GFP+ mice are shown 8-10 weeks after transplant with varying amounts (1:1 or 1:4) 
of BM cells of WT and sB1-/- donors relative to the percentage of sB1-/- input. The 
dotted line indicates negative correlation between sB1-/- input and total PMN 
numbers. (C) The relative percentage of cells from each donor is shown for PMNs 
and B cells from irradiated GFP+ mice 8-10 weeks after transfer of 1:1 mixture of WT 
(CD45.1) and CG.sB1-/- (CD45.2) BM. Data points are indicated for each mouse and 
means were compared by paired Student’s t-test. (D) Survival of WT and sB1-/- PMNs 
in vitro in the presence of human CG for 3hr in serum-free medium. Percentage of 
live cells (mean±SD) of 2-5 independent experiments were compared by two-way 
ANOVA with Bonferroni post-test. 
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Figure 4. sB1-/- PMN death mediated by CG does not require caspase activity. 
Survival of isolated BM PMNs in the presence of 50µM pan-caspase inhibitor Q-VD-
OPh was measured by flow cytometry (Suppl Fig.S1) at indicated time points for (A) 
WT and sB1-/- PMNs (N=3) and (B) CG-/- and CG-/-.sB1-/- PMNs (N=2). Data is shown 
as mean ± SD and was analyzed by two-way ANOVA followed by Bonferroni post 
test (*** P<0.001). 
 
  
A B 
  20 
 
 
Figure 5. LMP induces CG-mediated death in PMNs. BM cells of indicated 
genotypes were incubated with 100µM of LLME only (A) or 100µM LLME and 50µM 
Q-VD-OPh (B). Percentage of surviving PMNs was determined by flow cytometry. 
Data is shown as mean ± SEM (N=3-5) and was analyzed by two-way ANOVA 
followed by Bonferroni post-test (* P<0.05, ** P<0.01, *** P<0.001). 
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Figure 6. In vivo G-CSF therapy increases PMN numbers in BM of sB1-/- mice. 
BM PMN (A), myelocyte (B) and blood PMN (C) numbers were determined 24hr after 
recombinant murine G-CSF therapy for 5 consecutive days. Filled and open circles 
represent cell numbers of individual WT and sB1-/- female mice, respectively. 
Untreated females (Fig.2 subset) were similar to saline control females and were 
compared to the G-CSF treated mice. Statistical analysis was performed using two-
way ANOVA with Bonferroni post test. (** P<0.01; *** P<0.001). 
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